A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of 2 Dose Regimens of Intravenous TAK-954 for the Prophylaxis and Treatment of Postoperative Gastrointestinal Dysfunction in Patients

Grants and Contracts Details

StatusFinished
Effective start/end date5/14/19 → 3/21/22

Funding

  • Pharmaceutical Research Associates: $51,741.00